Adlai Nortye

Adlai NortyeANL

Price

$ 3.37

Market Capitalization

$ 143.14 M

Shares Outstading

42.474 M

Change

$ -0.01

Percentage Change

-0.33 %

Country

Cayman Islands 🌐

Industry

Biotechnology

Healthcare

Exchange

NASDAQ

IPO

2000-01-03

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent

Revenue of Adlai Nortye ( ANL)

Revenue : $ 0.00

Adlai Nortye has Revenue of $ 0.00 .The current price of Adlai Nortye is $3.37 (-0.33 %). Revenue of a stock refers to the income generated by the company that the stock represents. It can come from various sources such as sales of products or services, interest on investments, or other business activities.
Revenue of Adlai Nortye from 2021 to 2024
Year on Year Revenue of Adlai Nortye
Revenue
YearRevenueChange %
31-12-2023$ 0.000%
31-12-2022$ 0.00-100%
31-12-2021$ 45.73 M
Market Cap of Magnificent 7

Stock Ticker

Market Cap

Price

Change

Price(30 Days)

Country

$ 3.289 T

$ 442.57

0.22%

$ 0.99

United States🇺🇸

$ 3.258 T

$ 212.49

-0.82%

$ -1.75

United States🇺🇸

$ 3.244 T

$ 131.88

1.75%

$ 2.27

United States🇺🇸

$ 2.193 T

$ 178.37

0.92%

$ 1.63

United States🇺🇸

$ 1.911 T

$ 183.66

-0.09%

$ -0.17

United States🇺🇸

$ 1.787 T

$ 7.38312

-0.10%

$ -0.01

Saudi Arabia🇸🇦

$ 1.279 T

$ 504.16

0.01%

$ 0.06

United States🇺🇸

NEWSLETTER

MarketStreak weekly Newsletter

Get weekly Stock Market/Crypto News and Jobs updates directly to your inbox.

MarketStreak Research

Research

Latest data-backed business trends, research insights, and industry analyses.

MarketStreak Inc.

TEXAS, USA 🇺🇸

Disclaimer : The content on our website, including hyperlinked sites, associated applications, forums, blogs, and social media accounts, is for general information only and sourced from third-party providers. We offer no warranties regarding the content's accuracy or updatedness. Please note that our content should not be considered financial or legal advice. Always conduct thorough research and consult with a financial advisor before making any decisions. Trading is a high-risk activity that can lead to significant losses, so please seek professional guidance before making any trading decisions. Our content is not meant to be a solicitation or offer.